Clinicopathologic and Molecular Characteristics of Hepatoid Adenocarcinoma of Bladder: a case report

Abstract

Background Hepatoid adenocarcinoma of bladder (HACD) is extremely rarely reported. Only 10 cases of HACD have been reported to date in English literature and no molecular analyses of HACD have ever been reported Case presentation: This case was a 57-year-old man who complained of gross hematuria for 5 days and urinary tract ultrasound examination revealed a hypoechoic mass at the right lateral wall of the bladder. 10 months later, the tumor recurred and transurethral resection was performed again. Definitive diagnosis of HACD was made by morphological and immunohistochemical analysis. A comparison was made between those two resections by the next generation sequencing (NGS). Somatic mutations of TP53, RB1 and KMT2D and amplifications of CCND1 and FGFR1 were identified in both resections. FGFR3 amplification was detected in the recurrent resection. Conclusions Detection of amplifications of FGFR1 and FGFR3 suggests that the FGFR pathway may play an important role in HACD and could be a candidate for personalized treatment. In this report, we provide some useful molecular clues to the analysis of HACD, while the mechanism and treatment still need to be explored.

Hepatoid Adenocarcinoma of the Lung

“…21 Morphologically, the HAL tumor tissue contains adenocarcinoma region, hepatoid region and undifferentiated region. 9 In the undifferentiated area, the tumor cells are large and homogeneous with clear boundaries and slightly eosinophilic cytoplasm. The nuclei of these cells are large, irregularly inclined to one side with a thick nuclear membranes, 1 to 3 nucleoli and coarse granular chromatins.…”

“…Generally, the treatment strategy for HAL refers to those commonly used for non-small cell lung cancer (NSCLC), including surgery, chemoradiotherapy, targeted therapy and immunotherapy. 9,10 However, the prognosis of HAL patient remains poor. 11…”